Nabriva Therapeutics announced the initiation of a clinical Phase I trial for BC-3781, a pleuromutilin antibiotic being developed to treat serious infections including complicated skin and skin structure infections and community-acquired pneumonia. The clinical study is designed to evaluate the safety and tolerability of BC-3781 in humans via intravenous administration.
The antibiotic is highly active against key gram-positive pathogens, including MRSA, and gram-negative pathogens associated with community-acquired pneumonia. Its novel mode of action ensures that it overcomes resistance mechanisms affecting all approved classes of antibiotics. In addition it belongs to the first generation of pleuromutilins to combine availability of both oral and i.v. dosage forms.
Dr. David Chiswell, CEO of Nabriva Therapeutics said: “In 2009 we intend to generate key human data for our two lead pleuromutilin-based antibiotics, BC-3205 and BC-3781. The BC-3205 oral administration clinical trial is already underway and we are delighted now to be also commencing the trial for intravenously administered BC-3781. Of particular note is that this is the first time a pleuromutilin antibiotic has been administered via the intravenous route opening the possibility for pleuromutilin based step-down therapy.”
